This “Sialorrhoea - Pipeline Insight, 2021” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Sialorrhoea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Sialorrhea, drooling or excessive salivation is a common problem in neurologically impaired children and in adults who have Parkinson's disease or have had a stroke. It is most commonly caused by poor oral and facial muscle control. Sialorrhea can lead to significant physical and psychosocial complications, including perioral chapping, dehydration, infection, foul odor, stigmatization, and increased dependency and level of care, all of which can create an additional burden for these medically complicated patients. Sialorrhea usually is caused by neuromuscular dysfunction, hypersecretion, sensory dysfunction, or anatomic (motor) dysfunction. The most common cause is neuromuscular dysfunction. Anterior sialorrhea is diagnosed by the observation of excessive drooling. Posterior sialorrhea can be suggested by the history of choking and repeated pneumonias. Treatment for Sialorrhea range from conservative (i.e., observation, postural changes, biofeedback) to more aggressive measures such as medication, radiation, and surgical therapy.
"Sialorrhoea - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sialorrhoea pipeline landscape is provided which includes the disease overview and Sialorrhoea treatment guidelines. The assessment part of the report embraces, in depth Sialorrhoea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sialorrhoea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Sialorrhoea R&D. The therapies under development are focused on novel approaches to treat/improve Sialorrhoea.
This segment of the Sialorrhoea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
NT0502: Aytu BioPharma
NT0502 (N-desethyloxybutynin) is an oral, once- or twice-daily potential treatment to reduce chronic sialorrhea in patients with neurological and other conditions associated with drooling and excessive salivation. Based on preclinical data, NT0502 offers the potential for an improved tolerability profile and an easier-to-dose oral formulation, without the need for complex titration, compared to existing treatment options. NT0502 is an active metabolite of oxybutynin, an approved drug to treat a urological condition. NT0502 in Phase 1 clinical development for treatment of chronic sialorrhea.
This segment of the report provides insights about the different Sialorrhoea drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 3+ key companies which are developing the therapies for Sialorrhoea. The companies which have their Sialorrhoea drug candidates in the most advanced stage, i.e. Phase I include, Aytu BioPharma.
Phases
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Sialorrhoea: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sialorrhoea therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sialorrhoea drugs.
Geography Covered
- Global coverage
Sialorrhoea Understanding
Sialorrhoea: Overview
Sialorrhea, drooling or excessive salivation is a common problem in neurologically impaired children and in adults who have Parkinson's disease or have had a stroke. It is most commonly caused by poor oral and facial muscle control. Sialorrhea can lead to significant physical and psychosocial complications, including perioral chapping, dehydration, infection, foul odor, stigmatization, and increased dependency and level of care, all of which can create an additional burden for these medically complicated patients. Sialorrhea usually is caused by neuromuscular dysfunction, hypersecretion, sensory dysfunction, or anatomic (motor) dysfunction. The most common cause is neuromuscular dysfunction. Anterior sialorrhea is diagnosed by the observation of excessive drooling. Posterior sialorrhea can be suggested by the history of choking and repeated pneumonias. Treatment for Sialorrhea range from conservative (i.e., observation, postural changes, biofeedback) to more aggressive measures such as medication, radiation, and surgical therapy.
"Sialorrhoea - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sialorrhoea pipeline landscape is provided which includes the disease overview and Sialorrhoea treatment guidelines. The assessment part of the report embraces, in depth Sialorrhoea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sialorrhoea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Sialorrhoea R&D. The therapies under development are focused on novel approaches to treat/improve Sialorrhoea.
Sialorrhoea Emerging Drugs Chapters
This segment of the Sialorrhoea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sialorrhoea Emerging Drugs
NT0502: Aytu BioPharma
NT0502 (N-desethyloxybutynin) is an oral, once- or twice-daily potential treatment to reduce chronic sialorrhea in patients with neurological and other conditions associated with drooling and excessive salivation. Based on preclinical data, NT0502 offers the potential for an improved tolerability profile and an easier-to-dose oral formulation, without the need for complex titration, compared to existing treatment options. NT0502 is an active metabolite of oxybutynin, an approved drug to treat a urological condition. NT0502 in Phase 1 clinical development for treatment of chronic sialorrhea.
Sialorrhoea: Therapeutic Assessment
This segment of the report provides insights about the different Sialorrhoea drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Sialorrhoea
There are approx. 3+ key companies which are developing the therapies for Sialorrhoea. The companies which have their Sialorrhoea drug candidates in the most advanced stage, i.e. Phase I include, Aytu BioPharma.
Phases
This report covers around 3+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Sialorrhoea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Sialorrhoea: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sialorrhoea therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sialorrhoea drugs.
Sialorrhoea Report Insights
- Sialorrhoea Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Sialorrhoea Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Sialorrhoea drugs?
- How many Sialorrhoea drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sialorrhoea?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Sialorrhoea therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Sialorrhoea and their status?
- What are the key designations that have been granted to the emerging drugs?
Table of Contents
IntroductionExecutive Summary
Sialorrhoea: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Late Stage Products
- Comparative Analysis
Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products
- Comparative Analysis
OC oral solution: Orient Pharma
- Product Description
- Research and Development
- Product Development Activities
Early stage products
- Comparative Analysis
NT0502: Aytu BioPharma
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Sialorrhoea Key Companies
Sialorrhoea Key Products
Sialorrhoea- Unmet Needs
Sialorrhoea- Market Drivers and Barriers
Sialorrhoea- Future Perspectives and Conclusion
Sialorrhoea Analyst Views
Sialorrhoea Key Companies
AppendixList of Tables
Table 1 Total Products for Sialorrhoea
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Sialorrhoea
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Nobelpharma
- Aytu BioPharma
- NeuroHealing Pharmaceuticals
- Orient Pharma
